EANS-News: november Aktiengesellschaft / PROGEN Biotechnik GmbH - Significant Increase of 3rd Quarter Operating Results

• PROGEN Biotechnik GmbH reports significant sales increase

• Significant increase in operating profit

• Significantly improved margins

• Consolidated results nearly break-even

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Annual Reports/Financial Figures/Balance Sheet/quarterly
report/9-month report

Subtitle: • PROGEN Biotechnik GmbH reports significant sales increase
• Significant increase in operating profit
• Significantly improved margins
• Consolidated results nearly break-even

Cologne (euro adhoc) - november AG, Cologne, listed in the Prime
Standard of the German Stock Exchange (WKN A0Z24E) is publishing
figures for the first nine month of 2010 on November 12, 2010.
Especially promising are the HRB (DVFA/SG) results of PROGEN
Biotechnik GmbH, the major holding of the november AG. Measures taken
and increased sales activities of PROGEN show considerably positive
effects in the 3rd quarter of 2010.

July through September sales revenues and other operating income show
an increase of TEUR 170 to TEUR 1.221, i.e. approx 16.2% as compared
to the same period last year (TEUR 1.051). At the same time, PROGEN´s
3rd quarter operating profit of TEUR 187 are significantly higher as
compared to the same period last year (TEUR 102), i.e. an increase of
approx. 83.3%. This disproportional profit increase is a result of
improved margins because of higher sales and only slightly increased
purchase prices and nearly constant operating costs.

This positive trend of PROGEN is also confirmed by direct comparison
of the 2nd and 3rd quarter of 2010. The HGB turnover and other
operating income increased from TEUR 1.102 to TEUR 1.221 and
operating profits from TEUR -11 to TEUR 187. PROGEN Biotechnik
expects this positive trend to continue also in Q4.

Overall, these developments also have significantly positive effects
on the consolidated results: 3rd quarter figures are nearly
break-even. november AG is now on a solid course for profitable
growth. For a detailed Q3 report 2010, please refer to:
www.november.de/berichte

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: november Aktiengesellschaft
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Dirk Zurek

Vorstand

Tel.: +49 (0) 221 82200 520 10

E-Mail: ir@november.de

Branche: Biotechnology
ISIN: DE000A0Z24E9
WKN: A0Z24E
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade